Regeneron Pharmaceuticals REGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.42B-1.8% | $4.5B-1.6% | $4.58B+2.7% | $4.46B-0.9% | $4.5B+2.0% | ||
| $540M-0.7% | $543.7M+3.5% | $525.1M+2.9% | $510.1M+2.9% | $495.7M+2.7% | ||
| $995.4M+0.2% | $993.7M-5.3% | $1.05B+1.1% | $1.04B+2.8% | $1.01B+2.6% | ||
| —— | —— | —— | —— | $343M-38.1% | ||
| $98.5M-64.5% | $277.4M-29.8% | $395.1M-17.2% | $476.9M-22.6% | $616.2M-0.6% | ||
| $1.08B+42.3% | $761.5M-22.9% | $987.1M+134% | $422.3M+2.9% | $410.5M-44.2% | ||
| —— | —— | —— | -$82.2M-155% | $149.8M-39.8% | ||
| $5.01B+0.7% | $4.98B-1.8% | $5.07B+6.9% | $4.74B+20.0% | $3.95B-10.6% | ||
| $899.7M+0.1% | $898.4M+5.8% | $849.3M-4.6% | $889.8M+4.5% | $851.3M+12.6% | ||
| —— | —— | —— | —— | —— | ||
| $374.3M+1.1% | $370.3M+33.4% | $277.6M+48.9% | $186.4M+98.7% | $93.8M— | ||
| $3.19B-7.2% | $3.44B-8.1% | $3.74B-1.9% | $3.81B+13.6% | $3.35B+28.8% | ||
| $738.4M+16.1% | $635.9M+185% | $223.3M-49.0% | $437.7M-48.1% | $843.8M-42.4% | ||
| $601M+12.9% | $532.1M+99.8% | $266.3M-30.6% | $383.5M-44.4% | $689.7M-33.0% | ||
| -$3.43B+7.7% | -$3.72B+8.7% | -$4.07B-2.1% | -$3.99B-19.5% | -$3.34B-51.6% | ||
| —— | —— | —— | $1.1M+175% | $400K+157% | ||
| -$122.4M-119% | $634.7M— | —— | —— | —— | ||
| —— | $41.6M-6.2% | $44.35M-5.8% | $47.1M-5.5% | $49.85M-5.2% | ||
| $742.3M-5.5% | $785.4M-5.7% | $833.1M+15.2% | $723.1M+2.4% | $706M-6.8% | ||
| —— | —— | $513.4M— | —— | —— | ||
| -$187.9M-38.7% | -$135.5M-103% | -$66.6M-213% | -$21.3M+45.7% | -$39.2M-8.6% | ||
| $322M+2.1% | $315.3M-7.5% | $340.7M+14.6% | $297.4M+112% | $140M+11.4% | ||
| —— | —— | —— | —— | -$43.7M-30.8% | ||
| $4.11B+0.8% | $4.08B-3.3% | $4.22B+9.5% | $3.85B+24.2% | $3.1B-15.4% | ||
| $4.11B+0.8% | $4.08B-3.3% | $4.22B+9.5% | $3.85B+24.2% | $3.1B-15.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regeneron Pharmaceuticals generate?
- Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.
- What is Regeneron Pharmaceuticals's free cash flow?
- After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.
- Where does Regeneron Pharmaceuticals's cash flow data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
